- Home
- ACRV vs RMAX Comparison
ACRV vs RMAX Comparison
Compare ACRV & RMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- RMAX
- Stock Information
- Founded
- ACRV 2018
- RMAX 1973
- Country
- ACRV United States
- RMAX United States
- Employees
- ACRV N/A
- RMAX N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- RMAX Real Estate
- Sector
- ACRV Health Care
- RMAX Finance
- Exchange
- ACRV Nasdaq
- RMAX Nasdaq
- Market Cap
- ACRV 170.3M
- RMAX 200.2M
- IPO Year
- ACRV 2022
- RMAX 2013
- Fundamental
- Price
- ACRV $5.65
- RMAX $10.07
- Analyst Decision
- ACRV Strong Buy
- RMAX Hold
- Analyst Count
- ACRV 5
- RMAX 4
- Target Price
- ACRV $22.40
- RMAX $9.17
- AVG Volume (30 Days)
- ACRV 50.9K
- RMAX 161.7K
- Earning Date
- ACRV 11-13-2024
- RMAX 02-20-2025
- Dividend Yield
- ACRV N/A
- RMAX N/A
- EPS Growth
- ACRV N/A
- RMAX N/A
- EPS
- ACRV N/A
- RMAX N/A
- Revenue
- ACRV N/A
- RMAX $311,818,000.00
- Revenue This Year
- ACRV N/A
- RMAX N/A
- Revenue Next Year
- ACRV N/A
- RMAX $0.81
- P/E Ratio
- ACRV N/A
- RMAX N/A
- Revenue Growth
- ACRV N/A
- RMAX N/A
- 52 Week Low
- ACRV $3.19
- RMAX $6.94
- 52 Week High
- ACRV $11.90
- RMAX $14.31
- Technical
- Relative Strength Index (RSI)
- ACRV 41.71
- RMAX 40.93
- Support Level
- ACRV $5.36
- RMAX $10.25
- Resistance Level
- ACRV $6.00
- RMAX $10.23
- Average True Range (ATR)
- ACRV 0.52
- RMAX 0.41
- MACD
- ACRV -0.01
- RMAX 0.03
- Stochastic Oscillator
- ACRV 17.74
- RMAX 50.82
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.